(Total Views: 811)
Posted On: 02/22/2017 3:39:49 PM
Post# of 72447
Can't wait to see the endoscopic data on cohort 2. Bring on March Madness!
Leo Ehrlich, Chief Executive Officer at Cellceutix commented, “We raised a lot of eyebrows at meetings at the Biotech Showcase conference last week and are capturing the attention of Big Pharma with preliminary reports and scopes. Seeing the before and after endoscopic videos from patients in Cohort 1 is the most encouraging support of Brilacidin’s potential for treating IBD. I am proud to say that to date, every patient in this trial has benefited from their Brilacidin treatment.”
http://www.cellceutix.com/press-release/2017/...el-disease
Leo Ehrlich, Chief Executive Officer at Cellceutix commented, “We raised a lot of eyebrows at meetings at the Biotech Showcase conference last week and are capturing the attention of Big Pharma with preliminary reports and scopes. Seeing the before and after endoscopic videos from patients in Cohort 1 is the most encouraging support of Brilacidin’s potential for treating IBD. I am proud to say that to date, every patient in this trial has benefited from their Brilacidin treatment.”
http://www.cellceutix.com/press-release/2017/...el-disease
(0)
(0)
